Adeno-associated virus (AAV) vector has been successfully applied in patients with blindness and hemophilia. While significant progress continues to be made in AAV vector mediated gene delivery in clinical trials, several challenges remain in improving AAV transduction efficiency, tropism, and immunity to the AAV capsid and transgene. The main research focus of the Li lab is to develop effective strategies to overcome these barriers and enhance AAV transduction.